| Paul M Ridker | Center for Cardiovascular Disease Prevention (P.M. Ridker, and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital Harvard Medical School (Y.G., Harvard T.H. Chan School of Public Health Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., MA and Institute of Public Health (T.K.), Charite Universitatsmedizin Berlin |
| Samia Mora | Center for Cardiovascular Disease Prevention (P.M. Ridker, and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital Harvard Medical School (Y.G., Harvard T.H. Chan School of Public Health Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., MA and Institute of Public Health (T.K.), Charite Universitatsmedizin Berlin |
| Daniel I Chasman | Center for Cardiovascular Disease Prevention (P.M. Ridker, and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital Harvard Medical School (Y.G., Harvard T.H. Chan School of Public Health Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., MA and Institute of Public Health (T.K.), Charite Universitatsmedizin Berlin |
| Daniel I Chasman | Center for Cardiovascular Disease Prevention (P.M. Ridker, and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital Harvard Medical School (Y.G., Harvard T.H. Chan School of Public Health Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., MA and Institute of Public Health (T.K.), Charite Universitatsmedizin Berlin |